Expression of lymphocyte-endothelial receptor-ligand pairs, α4β7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease

Gut

Volumn 45, Issue 6, 1999, Pages 856-863

  Souza, H S ^a,d   Elia, C C S ^a   Spencer, J ^b   MacDonald, T T ^c  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d NONE   (Brazil)

Author keywords

Adhesion molecules; Inflammatory bowel disease; Mucosal immunity; T lymphocytes

Indexed keywords

ALKALINE PHOSPHATASE; CD3 ANTIGEN; HYBRID PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIGAND; LYMPHOCYTE RECEPTOR; METHOTREXATE; METRONIDAZOLE; MONOCLONAL ANTIBODY CD3; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CELL DENSITY; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENDOTHELIUM CELL; ENTERITIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE ENDOSCOPY; IRRITABLE COLON; JEJUNUM BIOPSY; LAMINA PROPRIA; LEUKOCYTE MIGRATION; LYMPHOCYTE; MALE; MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULCERATIVE COLITIS;

EID: 0032733508     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.45.6.856     Document Type: Article

References (45)

1. Koizumi M, King N, Lobb R, et al. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 1992;103:840-7.
2. Nakamura S, Ohtani H, Watanabe Y, et al. In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells. Lab Invest 1993;69:77-85.
3. Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in inflammatory bowel disease. Gut 1995;36:724-30.
4. Malizia G, Calabrese A, Cottone M, et al. Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology 1991;100:150-9.
5. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110.
6. Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell 1990;62:3-6.
7. Nielsen OH, Rask-Madsen J. Mediators of inflammation in chronic inflammatory bowel disease. Scand J Gastroenterol 1996;31(suppl 216):149-59.
8. Van Deventer JSH. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
9. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-β by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn's disease. Gut 1989;30:835-8.
10. MacDonald TT, Hutchings P, Choy MY, et al. Tumour necrosis factor-alpha and interferon gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
11. Ligumski M, Simon PL, Karmeli F, et al. Role of interleukin 1 in inflammatory bowel disease enhanced production during active disease. Gut 1990;31:686-9.
12. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95.
13. Youngman KR, Simon PL, West GA, et al. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993;104:749-58.
14. Sikorski EE, Hallmann R, Berg EL, et al. The Peyer's patch endothelial receptor for lymphocytes, the mucosal vascular addressin, is induced on a murine endothelial cell line by tumour necrosis factor-alpha and IL-1. J Immunol 1993;51:5239.
15. Hanninen A, Taylor C, Strecter PR, et al. Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium. J Clin Invest 1993;92:2509-15.
16. Viney JL, Jones S, Chiu HH, et al. Mucosal addressin cell adhesion molecule-1: a structural and functional analysis demarcates the integrin binding motif. J Immunol 1996;157:2488-97.
17. McDonald SAC, Palmen MJHJ, Van Rees EP, et al. Characterisation of the mucosal cell-mediated immune response in IL-2 knockout mice before and after the onset of colitis. Immunology 1997;91:73-80
18. mgt. CD4+ T cells. J Immunol 1997;158:2099-106.
19. Paterson DJ, Jefferies WA, Green JR, et al. Antigens of activated rat lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol 1987;24:1281-90.
20. Mallet S, Fossum S, Barclay AN. Characterisation of the MRC OX40 antigen of activated CD4 positive T lymphocytes - a molecule related to nerve growth factor receptor. EMBO J 1900;9:1063-8.
21. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994;76:959-62.
22. Stüber E, Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 1996;183:979-89.
23. Ohshima Y, Tanaka Y, Tozawa H, et al. Expression and function of OX40 ligand on human dendritic cells. J Immunol 1997;159:3838-48.
24. Godfrey WR, Fagnoni F, Harara MA, et al. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumour necrosis factor. J Exp Med 1994;180:757-62.
25. Imura A, Hori T, Imada K, et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 1996;183:2185-95.
26. Pender SLF, MacDonald TT. Lamina propria T cells. In: MacDonald TT, ed. Chemical immunology - mucosal T cells. Basel: Karger, 1998:103-17.
27. Mekhijian HS, Switz DM, Melnyk CS, et al. Clinical features and natural history of Crohn's disease. Gastroenterology 1979;77;898-906.
28. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980;i:514.
29. Truelove SC, Witts LF. Cortisone in ulcerative colitis: a final report on a therapeutic trial. BMJ 1955;ii:1041-8.
30. Ferguson R, Allan RN, Cooke WT. A study of the cellular infiltrate of the proximal jejunal mucosa in ulcerative colitis and Crohn's disease. Gut 1975;16:205-8.
31. Goodman MJ, Skinner JM, Truelove SC. Abnormalities in the apparently normal bowel mucosa in Crohn's disease. Lancet 1976;i:275-8.
32. Van Spreeuwell JP, Lindeman J, Van Der Val AM, et al. Morphological and immunohistochemical findings in upper gastrointestinal biopsies of patients with Crohn's disease of the ileum and colon. J Clin Pathol 1982;35:934-40.
33. Ahrenstedt O, Knutson L, Nilsson B, et al. Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N Engl J Med 1990;322:1345-9.
34. Reimund J-M, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-α, interleukin 1-β, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39:684-9.
35. Wagtmans MJ, Van Hogezand RA, Griffioen G, et al. Crohn's disease of the upper gastrointestinal tract. Neth J Med 1997;50:S2-7.
36. Oberhuber G, Hirsch M, Stolte M. High incidence of upper gastrointestinal tract involvement in Crohn's disease. Virchows Arch 1998;432;49-52.
37. Brynskov J, Tvede N, Andersen CB, et al. Increased concentrations of interleukin 1β, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992;33:55-8.
38. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
39. Schweighoffer T, Tanaka Y, Tidswell M, et al. Selective expression of integrin α4β7 on a subset of human CD4+ memory T cells with hallmarks of gut-tropism. J Immunol 1993;151:717-29.
40. Hamann A, Andrew DP, Jablonski-Westrich D, et al. Role of α4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol 1994;152;3282-93.
41. Baum PR, Gayle III RB, Ramsdell F, et al. Molecular characterisation of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein. EMBO J 1994;13:3992-4001.
42. Weinberg AD, Wallin JJ, Jones RE, et al. Target organ specific upregulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with EAE. J Immunol 1994;152:4712-21.
43. Weinberg AD, Bourdette DN, Sullivan TJ, et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 1996;2:183-9
44. Higgins LM, McDonald SAC, Whittle N, et al. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: prevention of ongoing inflammatory bowel disease with and OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol 1999;162:486-93.
45. Stuber E, Von Freier A, Marinescu D, et al. Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine graft-versus-host disease. Gastroenterology 1998;115:1205-15.